FBRX — Forte Biosciences Share Price
0.000.00%
Last trade - 00:00- $45.82m
- -$12.54m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.87 | ||
| Price to Tang. Book | 0.87 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -69.74% | ||
| Return on Equity | -80.82% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Directors
- Paul Wagner CHM (50)
- Antony Riley CFO (54)
- Thomas Darcy IND (71)
- Lawrence Eichenfield IND (63)
- Steven Kornfeld IND (53)
- Patricia Walker IND (62)
- Donald Williams IND (62)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 24th, 2007
- Public Since
- April 13th, 2017
- No. of Shareholders
- 177
- No. of Employees
- 14
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 6,583,382
- Address
- 3060 PEGASUS PARK DRIVE, BUILDING 6, DALLAS, 75247
- Web
- https://www.fortebiorx.com/home/default.aspx
- Phone
- +1 3106186994
- Auditors
- Mayer Hoffman & McCann P.C.
Upcoming Events for FBRX
Q2 2025 Forte Biosciences Inc Earnings Release
Q2 2025 Forte Biosciences Inc Earnings Release
Forte Biosciences Inc Annual Shareholders Meeting
Similar to FBRX
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Forte Biosciences share price?
As of Today at 20:41 UTC, shares in Forte Biosciences are trading at $6.96. This share price information is delayed by 15 minutes.
How has the Forte Biosciences share price performed this year?
Shares in Forte Biosciences last closed at $6.96 and the price had moved by -59.66% over the past 365 days. In terms of relative price strength the Forte Biosciences share price has underperformed the S&P500 Index by -63.63% over the past year.
What are the analyst and broker recommendations for Forte Biosciences?
The overall consensus recommendation for Forte Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Forte Biosciences dividend yield?
Forte Biosciences does not currently pay a dividend.
Does Forte Biosciences pay a dividend?
Forte Biosciences does not currently pay a dividend.
When does Forte Biosciences next pay dividends?
Forte Biosciences does not currently pay a dividend.
How do I buy Forte Biosciences shares?
To buy shares in Forte Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Forte Biosciences?
As of the previous close price of $6.96, shares in Forte Biosciences had a market capitalisation of $45.82m.
Where are Forte Biosciences shares listed?
Here are the trading details for Forte Biosciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: FBRX
What kind of share is Forte Biosciences?
Based on an overall assessment of its quality, value and momentum Forte Biosciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Forte Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Forte Biosciences is $59.00. That is 747.7% above the last closing price of $6.96.
Analysts covering Forte Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$3.60 for the next financial year.
Find out moreWhat is the trend in the Forte Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Forte Biosciences. Over the past six months, its share price has outperformed the S&P500 Index by +67.27%.
As of the last closing price of $6.96, shares in Forte Biosciences were trading -34.56% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Forte Biosciences PE Ratio?
The Forte Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.96.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Forte Biosciences?
Forte Biosciences' management team is headed by:
- Paul Wagner - CHM
- Antony Riley - CFO
- Thomas Darcy - IND
- Lawrence Eichenfield - IND
- Steven Kornfeld - IND
- Patricia Walker - IND
- Donald Williams - IND